Therapeutic implications of vitamin D and calcium in overweight women with polycystic ovary syndrome.
OBJECTIVE
To assess effects of vitamin D and Calcium (Ca) on hormonal and metabolic milieu of polycystic ovary syndrome (PCOS).


METHODS
Single arm open label trial.


METHODS
Twelve overweight and vitamin D deficient women with PCOS underwent a 2 hour oral glucose tolerance testing at baseline and following 3-month supplementation with vitamin D (daily dose of 3533 IU, increased to 8533 IU after the first five participants) and 530 mg elemental Ca daily.


METHODS
Blood pressure (BP), plasma glucose, insulin, total testosterone (T) androstenedione (A), sex hormone binding globulin, lifestyle parameters were assessed at baseline and following 3-month intervention. Insulin resistance (IR) and area under the curve for glucose and insulin were computed; paired analyses were conducted.


RESULTS
Improved serum 25OHD (p < 0.001) and reductions in total T (p = 0.036) and A (p = 0.090) levels were noted following 3-month supplementation, compared to baseline. Significant lowering in BP parameters was seen in participants with baseline BP ≥ 120/80 mmHg (n = 8) and in those with baseline serum 25OHD ≤20 ng/ml (n = 9). Parameters of glucose homeostasis and IR remained unchanged (p > 0.05).


CONCLUSIONS
Androgen and BP profiles improved followed three month intervention, suggesting therapeutic implications of vitamin D and Ca in overweight and vitamin D deficient women with PCOS.
Obstetrics, Gynecology & Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA. Lubna.pal@yale.edu
Lubna
L
Pal
Amber
A
Berry
Luisa
L
Coraluzzi
Erin
E
Kustan
Cheryl
C
Danton
Julia
J
Shaw
Hugh
H
Taylor
D015652:25-Hydroxyvitamin D 2 / Q000097:blood; D000328:Adult; D015992:Body Mass Index; D002112:Calcifediol / Q000097:blood; D002136:Calcium, Dietary / Q000009:adverse effects / Q000627:therapeutic use*; D002762:Cholecalciferol / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D015331:Cohort Studies; D019587:Dietary Supplements / Q000009:adverse effects; D004872:Ergocalciferols / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D017588:Hyperandrogenism / Q000209:etiology / Q000517:prevention & control; D006973:Hypertension / Q000209:etiology / Q000517:prevention & control; D050177:Overweight / Q000150:complications*; D010352:Patient Dropouts; D010865:Pilot Projects; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000178:diet therapy* / Q000378:metabolism / Q000503:physiopathology; D045165:Testosterone Congeners / Q000097:blood; D014808:Vitamin D Deficiency / Q000150:complications / Q000178:diet therapy*; D055815:Young Adult
D002136:Calcium, Dietary; D004872:Ergocalciferols; D045165:Testosterone Congeners; D002762:Cholecalciferol; D015652:25-Hydroxyvitamin D 2; D002112:Calcifediol